Health Care Distributors

McKesson

McKesson's stock target price cut

McKesson released FY2026 Annual Earnings on May 7 After-Market (EST), actual revenue USD 403.43 B (forecast USD 408.51 B), actual EPS USD 38.38 (forecast USD 35.205)

McKesson released FY2026 Q4 earnings on May 7 After-Market EST, actual revenue USD 96.3 B (forecast USD 101.38 B), actual EPS USD 13.71 (forecast USD 10.4575)

McKesson Predicts 2027 Profit Slightly Above Wall Street Expectations

Truist Financial Corp increased its holding in McKesson Corp to 73,869 shares

McKesson to Release FY2026 Q4 Earnings on May 7 After-Market EST, Forecast Revenue USD 101.38 B, EPS USD 10.4575

McKesson Obtains $5 Billion Credit Line and Terminates Old Ones

Ashton Thomas Private Wealth LLC increased its holdings in McKesson Corporation

BofA Securities Downgrades McKesson's Price Target, Stock Falls

McKesson Secures $2 Billion in New Senior Credit Financing

McKesson Subsidiary Signs Credit Agreement

DiaSorin Signs Exclusive Distribution Agreement with McKesson Medical-Surgical to Promote Molecular Point-of-Care Testing Platform

Advisor OS LLC significantly increased holdings in McKesson Corporation

McKesson's Chief Legal Officer Disposes of Company's Common Stock

Prospera Financial Services Inc increased its holding in McKesson

Kinsale Capital Group Increased Holdings in McKesson

McKesson released FY2026 9 Months earnings on February 4 After-Market EST, actual revenue USD 307.14 B, actual EPS USD 24.76

McKesson released FY2026 Q3 earnings on February 4 After-Market (EST), actual revenue USD 106.16 B (forecast USD 105.91 B), actual EPS USD 9.59 (forecast USD 8.7)

Mckesson reports 2026 Q3 revenue up 11%, net income up 35%

McKesson to Release FY2026 Q3 Earnings on February 4 After-Market EST, Forecast Revenue USD 105.91 B, EPS USD 8.794

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Ordinary dividend (cash)

Ex Date: 2026.06.01 (EST), Cash dividend 0.82 USD

McKesson Corporation (MCK.US) Fiscal Year 2026 Third Quarter Earnings Conference Call

McKesson Corporation (MCK.US) Fiscal Year 2026 Second Quarter Earnings Conference Call

McKesson Corporation (MCK.US) Fiscal Year 2026 First Quarter Earnings Conference Call

McKesson Corporation (MCK.US) Fiscal Year 2025 Fourth Quarter Earnings Conference Call

McKesson Corporation (MCK.US) Q3 Fiscal Year 2025 Earnings Conference Call

McKesson Corporation (MCK.US) Fiscal Year 2025 Second Quarter Earnings Conference Call

McKesson Corp. (MCK) shares fell 1.81% to $761.89, ending a five-day winning streak amid a broader market decline. The S&P 500 and Dow Jones dropped 0.67% and 0.65%, respectively. Despite the loss, McKesson's performance was better than competitors like Amazon, UnitedHealth, and CVS, which also saw declines. The stock remains 23.73% below its 52-week high of $999.00 reached on March 3rd.

MarketWatch Automated

S&P 500

Dow Jones Industrial Average

Amazon

Unitedhealth

CVS Health

Factset Research

McKesson Corp. Stock Outperforms Competitors Despite Losses On The Day

LABU

SBIO

McKesson (MCK) reported strong Q4 and full year earnings, with increased sales and net income, leading to a 1.79% rise in stock price to $760.57. Despite recent declines, long-term returns remain robust. Analysts suggest the stock is undervalued at $951.73, driven by earnings power and acquisitions. However, a DCF model indicates potential downside risk, emphasizing the need to weigh earnings against cash generation. Investors are encouraged to explore other opportunities in healthcare.

Simplywall

VanEck Pharmaceutical ETF

SPDR Pharmac

Direxion S&P Biotech Bull 3X

iShares US Pharma

SPDR S&P Biotech

SPDR S&P Health Equip

Invesco Pharmaceuticals ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

iShares US Medical Devices

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Assessing McKesson (MCK) Valuation After Strong Q4 And Full Year Earnings Results

Global Wealth Management Investment Advisory Inc. has acquired a new stake in McKesson Corporation (NYSE:MCK), purchasing 4,312 shares valued at approximately $3.54 million. Other institutional investors have also increased their positions in McKesson. Analysts have given the stock a consensus rating of "Moderate Buy" with an average price target of $963.20. Recent insider transactions include sales by executives, with McKesson's stock currently trading at $735.20 and a market cap of $88.37 billion.

Market Beat

Global Wealth Management Investment Advisory Inc. Purchases New Position in McKesson Corporation $MCK

McKesson Corp. (MCK) shares rose 1.31% to $734.69 on a mixed trading day, while the Dow Jones increased by 0.11% and the S&P 500 decreased by 0.16%. This rise ended a two-day losing streak, although the stock remains 26.46% below its 52-week high of $999.00. Compared to competitors, Amazon fell 1.18%, while UnitedHealth and CVS saw gains of 3.11% and 3.18%, respectively. Trading volume was 921,341, surpassing the 50-day average of 893,517.

McKesson Corp. Stock Outperforms Competitors On Strong Trading Day

McKesson Corp. (MCK) shares fell 1.48% to $725.17 on Monday, marking its second consecutive day of losses, while the S&P 500 and Dow Jones both rose 0.19%. The stock is currently 27.41% below its 52-week high of $999.00. In comparison, competitors like UnitedHealth Group and CVS Health saw gains, while Amazon.com also declined.

McKesson Corp. Stock Underperforms Monday When Compared To Competitors

McKesson Corporation (NYSE:MCK) has received an average rating of "Moderate Buy" from seventeen brokerages. Three analysts rated it as a hold, while fourteen recommended buying. The average 12-month price target is $970.73. Recent reports show mixed sentiments: JPMorgan lowered its target to $1,015 but maintained an overweight rating, while revenue fell short of expectations at $96.3 billion. Insider selling activity was noted, with significant shares sold by executives. Hedge funds have also adjusted their positions in McKesson, with some increasing their stakes.

JPMorgan Chase

Evercore

Raymond James Financial

Deutsche Bank AG

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

McKesson Corporation (NYSE:MCK) Given Average Rating of "Moderate Buy" by Brokerages

McKesson(MCK.US)